Practical Guidelines Management of Graves Ophthalmopathy.

Graves' ophthalmopathy is the most common extra-thyroid manifestation in patients with Graves' disease, based on inflammatory and autoimmune conditions in orbital tissue. This practical guideline was formed by a multidiciplinary team, and is intended to provide guidance for diagnosis and management of Graves' ophthalmopathy in daily clinical practice to improve quality of care and treatment outcome.

[1]  Q. Su,et al.  Corticosteroids for Graves' Ophthalmopathy: Systematic Review and Meta-Analysis , 2018, BioMed research international.

[2]  S. Pearce,et al.  2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism , 2018, European Thyroid Journal.

[3]  E. Tomero,et al.  SAT0601 Anti-il6-receptor tocilizumab in graves’ orbitopathy. multicenter study of 29 patients , 2018, Saturday, 16 JUNE 2018.

[4]  Фадеев Валентин Викторович,et al.  Review of American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. , 2017 .

[5]  Terry J. Smith,et al.  Teprotumumab for Thyroid‐Associated Ophthalmopathy , 2017, The New England journal of medicine.

[6]  W. Wiersinga.  Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy. , 2017, The lancet. Diabetes & endocrinology.

[7]  Guofang Chen,et al.  Interpretation of the 2016 European Thyroid Association/European Group on Graves′ Orbitopathy Guidelines for the management of Graves′ orbitopathy , 2016 .

[8]  W. Wiersinga,et al.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy , 2016, European Thyroid Journal.

[9]  Victor M Montori,et al.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. , 2011, Thyroid : official journal of the American Thyroid Association.

[10]  M. Nardi,et al.  Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. , 2008, European journal of endocrinology.

[11]  G. Hommel,et al.  Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. , 2005, The Journal of clinical endocrinology and metabolism.

[12]  C. Marcocci,et al.  Treating severe Graves' ophthalmopathy. , 1997, Bailliere's clinical endocrinology and metabolism.

[13]  M. Ranney,et al.  Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.